Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty: Two triple-switch case reports

Lombardi Carlo, Menzella Francesco, Passalacqua Giovanni

Research output: Contribution to journalArticle

Abstract

Severe asthma affects between 5 and 10% of patients with asthma worldwide and requires best standard therapies at maximal doses. A subgroup of patients remains refractory to all treatments. We describe two case reports with severe allergic asthma who progressively worsened over the years despite the best therapy. The patients were first treated with omalizumab, which was completely ineffective, and then with bronchial thermoplasty (BT), again without clinical benefit. Since our patients met the AIFA criteria for inclusion in mepolizumab treatment, a therapy with this anti-IL5 biological agent was initiated. In the first case (a 53-year-old female), after the second mepolizumab administration, symptoms improved progressively, with a reduction in the number and severity of exacerbations, so the patient could finally be discharged from hospital. At follow-up, it was possible to reduce oral corticosteroids and continuing with inhaled corticosteroids/long-acting beta-agonists and montelukast. The patient had only one exacerbation/year. Symptom control and quality of life improved significantly. In the second case report (a 55-year-old male), after the sixth mepolizumab administration, symptoms improved progressively, with a reduction in the number and severity of exacerbations. At follow-up, it was possible to reduce and stop oral corticosteroids, continuing with inhaled therapy and montelukast. Symptom control and quality of life improved significantly.These are the first cases of patients unresponsive to sequential omalizumab and BT but with good and prolonged clinical response to mepolizumab. Both cases suggest that also after the failure of two consecutive third-line treatments, a third treatment (mepolizumab) should be attempted.

Original languageEnglish
Article number100967
JournalRespiratory Medicine Case Reports
Volume29
DOIs
Publication statusPublished - 2020
Externally publishedYes

Fingerprint

montelukast
Adrenal Cortex Hormones
Asthma
Therapeutics
Quality of Life
mepolizumab
Omalizumab
Interleukin-5
Biological Factors

Keywords

  • Bronchial thermoplasty
  • Eosinophilia
  • Exacerbation
  • Mepolizumab
  • Omalizumab
  • Severe asthma

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty : Two triple-switch case reports. / Carlo, Lombardi; Francesco, Menzella; Giovanni, Passalacqua.

In: Respiratory Medicine Case Reports, Vol. 29, 100967, 2020.

Research output: Contribution to journalArticle

@article{cfe55e127ace450fb6ce0ae4ac907e08,
title = "Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty: Two triple-switch case reports",
abstract = "Severe asthma affects between 5 and 10{\%} of patients with asthma worldwide and requires best standard therapies at maximal doses. A subgroup of patients remains refractory to all treatments. We describe two case reports with severe allergic asthma who progressively worsened over the years despite the best therapy. The patients were first treated with omalizumab, which was completely ineffective, and then with bronchial thermoplasty (BT), again without clinical benefit. Since our patients met the AIFA criteria for inclusion in mepolizumab treatment, a therapy with this anti-IL5 biological agent was initiated. In the first case (a 53-year-old female), after the second mepolizumab administration, symptoms improved progressively, with a reduction in the number and severity of exacerbations, so the patient could finally be discharged from hospital. At follow-up, it was possible to reduce oral corticosteroids and continuing with inhaled corticosteroids/long-acting beta-agonists and montelukast. The patient had only one exacerbation/year. Symptom control and quality of life improved significantly. In the second case report (a 55-year-old male), after the sixth mepolizumab administration, symptoms improved progressively, with a reduction in the number and severity of exacerbations. At follow-up, it was possible to reduce and stop oral corticosteroids, continuing with inhaled therapy and montelukast. Symptom control and quality of life improved significantly.These are the first cases of patients unresponsive to sequential omalizumab and BT but with good and prolonged clinical response to mepolizumab. Both cases suggest that also after the failure of two consecutive third-line treatments, a third treatment (mepolizumab) should be attempted.",
keywords = "Bronchial thermoplasty, Eosinophilia, Exacerbation, Mepolizumab, Omalizumab, Severe asthma",
author = "Lombardi Carlo and Menzella Francesco and Passalacqua Giovanni",
year = "2020",
doi = "10.1016/j.rmcr.2019.100967",
language = "English",
volume = "29",
journal = "Respiratory Medicine Case Reports",
issn = "2213-0071",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty

T2 - Two triple-switch case reports

AU - Carlo, Lombardi

AU - Francesco, Menzella

AU - Giovanni, Passalacqua

PY - 2020

Y1 - 2020

N2 - Severe asthma affects between 5 and 10% of patients with asthma worldwide and requires best standard therapies at maximal doses. A subgroup of patients remains refractory to all treatments. We describe two case reports with severe allergic asthma who progressively worsened over the years despite the best therapy. The patients were first treated with omalizumab, which was completely ineffective, and then with bronchial thermoplasty (BT), again without clinical benefit. Since our patients met the AIFA criteria for inclusion in mepolizumab treatment, a therapy with this anti-IL5 biological agent was initiated. In the first case (a 53-year-old female), after the second mepolizumab administration, symptoms improved progressively, with a reduction in the number and severity of exacerbations, so the patient could finally be discharged from hospital. At follow-up, it was possible to reduce oral corticosteroids and continuing with inhaled corticosteroids/long-acting beta-agonists and montelukast. The patient had only one exacerbation/year. Symptom control and quality of life improved significantly. In the second case report (a 55-year-old male), after the sixth mepolizumab administration, symptoms improved progressively, with a reduction in the number and severity of exacerbations. At follow-up, it was possible to reduce and stop oral corticosteroids, continuing with inhaled therapy and montelukast. Symptom control and quality of life improved significantly.These are the first cases of patients unresponsive to sequential omalizumab and BT but with good and prolonged clinical response to mepolizumab. Both cases suggest that also after the failure of two consecutive third-line treatments, a third treatment (mepolizumab) should be attempted.

AB - Severe asthma affects between 5 and 10% of patients with asthma worldwide and requires best standard therapies at maximal doses. A subgroup of patients remains refractory to all treatments. We describe two case reports with severe allergic asthma who progressively worsened over the years despite the best therapy. The patients were first treated with omalizumab, which was completely ineffective, and then with bronchial thermoplasty (BT), again without clinical benefit. Since our patients met the AIFA criteria for inclusion in mepolizumab treatment, a therapy with this anti-IL5 biological agent was initiated. In the first case (a 53-year-old female), after the second mepolizumab administration, symptoms improved progressively, with a reduction in the number and severity of exacerbations, so the patient could finally be discharged from hospital. At follow-up, it was possible to reduce oral corticosteroids and continuing with inhaled corticosteroids/long-acting beta-agonists and montelukast. The patient had only one exacerbation/year. Symptom control and quality of life improved significantly. In the second case report (a 55-year-old male), after the sixth mepolizumab administration, symptoms improved progressively, with a reduction in the number and severity of exacerbations. At follow-up, it was possible to reduce and stop oral corticosteroids, continuing with inhaled therapy and montelukast. Symptom control and quality of life improved significantly.These are the first cases of patients unresponsive to sequential omalizumab and BT but with good and prolonged clinical response to mepolizumab. Both cases suggest that also after the failure of two consecutive third-line treatments, a third treatment (mepolizumab) should be attempted.

KW - Bronchial thermoplasty

KW - Eosinophilia

KW - Exacerbation

KW - Mepolizumab

KW - Omalizumab

KW - Severe asthma

UR - http://www.scopus.com/inward/record.url?scp=85075263321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075263321&partnerID=8YFLogxK

U2 - 10.1016/j.rmcr.2019.100967

DO - 10.1016/j.rmcr.2019.100967

M3 - Article

AN - SCOPUS:85075263321

VL - 29

JO - Respiratory Medicine Case Reports

JF - Respiratory Medicine Case Reports

SN - 2213-0071

M1 - 100967

ER -